VEGF-antagonism and Endothelial Function in Age-related Macular Degeneration (AMD)

Completed

• Conditions: Macular Degeneration
• Interventions: Drug: Bevacizumab; Other: No treatment; Drug: Ranibizumab

• Registration Number: NCT00727753
• Lead Sponsor: University of Zurich

Brief Summary

The objective of this study is to evaluate the effects of 2 intravitreal injections with Ranibizumab or Avastin on endothelial function in subjects with neovascular macular degeneration compared to patients with dry AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2008-07
• Study First Submitted: 2008-07-31
• Study First Submitted QC: 2008-08-01
• Study First Posted: 2008-08-04
• Primary Completion: 2012-12
• Study Completion: 2013-10
• Status Verified: 2015-05
• Last Update Submitted: 2015-05-27
• Last Update Posted: 2015-05-28

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 54

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Bevacizumab	Bevacizumab	-
Dry AMD	No treatment	-
Ranibizumab	Ranibizumab	-

Primary Outcome Measures

Name	Time	Method
Change of endothelial function after 2 intravitreal injections and 8 weeks follow-up with ranibizumab or bevacizumab in patients with neovascular macular degeneration compared to patients with dry AMD.	8 weeks

Secondary Outcome Measures

Name	Time	Method
Change in cardiovascular and ophthalmological parameters.	8 weeks	Secondary outcomes include evaluation of retinal thickness as measured by optical coherence tomography (OCT), change in best-corrected visual acuity (BCVA), "Early Treatment Diabetic Retinopathy Study" (ETDRS) letters, ambulatory blood pressure, vascular compliance, biomarkers of vascular function and platelet function.

Trial Locations

Locations (1)

University Hospital Zurich, Division of Cardiology; 🇨🇭 Zurich, ZH, Switzerland